BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology: NHL: Diffuse Large B-Cell Lymphoma (DLBCL) Disease Coverage

October 09, 2018

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cases. The disease occurs predominantly in older people, with a median age of diagnosis around 65 years, and has a slightly higher prevalence in men than in women. DLBCL is categorized as an aggressive form of NHL; after initial onset the cancer advances quickly and can be fatal if left untreated. However, prompt and suitable treatment can lead to cure in more than 50% of cases.

This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, and Pipeline modules.
Indications Covered: Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
Back to the top Back to the top